Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CARLSBAD, Calif., Feb. 13, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 3489404 approximately five minutes prior to the start time.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
